Posts

Vaccines Against Prostate Cancer:

Image
Cancer vaccines could transform treatment and prevention – but misinformation about mRNA vaccines threatens their potential Informed Prostate Cancer Support Group March 2026  |  Special Feature: Cancer Immunotherapy Feature Article · Immunotherapy From Proven Therapy to the mRNA Frontier A major new immunotherapy is heading toward FDA approval, mRNA cancer vaccines are entering pivotal trials, and a promising "tumor autovaccination" strategy has shown proof of concept — here is what the latest science means for men with prostate cancer. Prepared for IPCSG Members  |  March 2026  |  Reviewed against published peer-reviewed literature and official regulatory releases BLUF — Bottom Line Up Front The idea of using the immune system itself to fight prostate cancer is no longer just a promise — it is increasingly a reality. One therapeutic vaccine, Provenge® (sipuleucel-T), has been FDA-approve...

A Better Safety Net: How PSMA PET/MRI Is Catching Hidden High-Risk Disease in Men Choosing Active Surveillance or Focal Therapy

Image
A Pilot Study of 18F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease - Alam - The Prostate - Wiley Online Library Informed Prostate Cancer Support Group (IPCSG) Spring 2026  |  Volume XXIV  |  Imaging & Early-Stage Management Featured Research Review A landmark Northwestern University pilot trial — and a wave of supporting international research — shows that this advanced scan can find dangerous tumors standard MRI misses, changing one-in-three patients' treatment plans and dramatically boosting confidence for everyone involved. Compiled for the IPCSG Newsletter | March 2026 | Based on peer-reviewed research and FDA-approved clinical evidence Bottom Line Up Front (BLUF) A new pilot clinical trial from Northwestern University found that a next-generation scan — ¹⁸F-rhPSMA-7.3 PET/MRI (bran...

When Cancer Moves Without Warning:

Image
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy - Tsutsumi - The Prostate - Wiley Online Library Informed Prostate Cancer Support Group IPCSG Newsletter  ·  Patient Education Series Spring 2026 Vol. 28 / Treatment Monitoring Treatment Monitoring  ·  Advanced Prostate Cancer The Problem of PSA-Silent Progression A new study from Japan, along with a growing body of international research, reveals that a significant number of men on today's powerful hormone therapies can have cancer that spreads on imaging — even while their PSA levels look perfectly controlled. What does this mean for how you are being monitored? IPCSG Newsletter  ·  Research Summary for Patients and Families Bottom Line Up Front (BLUF) A critical gap in standard prostate cancer monitoring...

Low Testosterone and the Risk of Prostate Cancer Progression

Image
Informed Prostate Cancer Support Group IPCSG Newsletter March 2026 | Patient Education Series Active Surveillance & Hormonal Biology Low Testosterone and the Risk of Prostate Cancer Progression: A Surprising Twist on an Old Story A landmark study from MD Anderson Cancer Center turns decades of conventional wisdom on its head — finding that men with low testosterone may face greater risk of their prostate cancer becoming more aggressive while under watchful waiting. Prepared for the IPCSG Member Community  |  March 2026  |  Based on peer-reviewed research through March 2026 Bottom Line Up Front (BLUF) A new study of 924 men on active surveillance found that those with low testosterone (≤300 ng/dL) had a 61% higher risk of their cancer progressing to an aggressive Grade Group 3 or higher. This challenges the century-old belief that high testosterone "feeds" prostate cancer. New scien...